Omez FF-20 Tab

Side Effects of Omez FF-20 Tab

Increased risk of Clostridium difficile-associated diarrhoea (CDAD) and osteoporosis-related fractures. Headache, rash, pruritus, dizziness, fatigue, cough, back or abdominal pain, arthralgia and myalgia, urticaria, dry mouth, photosensitivity, bullous eruption, fever, angioedema, bronchospasm, anaphylaxis, somnolence, aggression and vertigo, insomnia, reversible confusional states, depression, agitation, hallucination. Increased liver enzyme, hepatitis, jaundice, hepatic encephalopathy. Rarely, candidiasis, paraesthesia, alopecia, muscular weakness, angina, tachycardia, bradycardia, blurred vision, alopecia, stomatitis, increased sweating, taste disturbances, peripheral oedema, malaise, hyponatraemia, hypomagnesaemia, blood disorders (e.g. agranulocytosis, leucopenia and thrombocytopenia), gynaecomastia, impotence and interstitial nephritis. Potentially Fatal: Anaphylaxis, pancreatitis, Stevens-Johnson syndrome, erythema multiforme and toxic epidermal necrolysis.

Drug Interactions

Increased risk of hypomagnesaemia w/ diuretics. May increase INR and prothrombin time w/ warfarin. Increased risk of digoxin-induced cardiotoxic effects. May increase plasma concentration benzodiazepines (e.g. diazepam), clarithromycin and methotrexate. Decreased absorption of itraconazole, ketoconazole, posaconazole, dasatinib, iron salts. May prolong elimination of diazepam, cilostazol, phenytoin and ciclosporin. May reduce the antiplatelet effect of clopidogrel. Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine, nelfinavir and atazanavir.

Contraindications

Concomitant use w/ rilpivirine, nelfinavir and atazanavir.

Mechanism of Action

Omeprazole is a substituted benzimidazole gastric antisecretory agent and is also known as PPI. It blocks the final step in gastric acid secretion by specific inhibition of H+/K+ ATPase enzyme system present on the secretory surface of the gastric parietal cell. Both basal and stimulated acid are inhibited. Onset: Approx 1 hr. Duration: Up to 72 hr. Absorption: Rapid but variably absorbed (oral). Bioavailability: Oral: Approx 30-40%. Time to peak plasma concentration: Approx 1-2 hr. Distribution: Plasma protein binding: Approx 95%. Metabolism: Hepatic metabolism via CYP2C19 isoenzyme to form hydroxyl-omeprazole and CYP3A4 to form omeprazole sulfone. Excretion: Mainly via urine (approx 77%), the remainder in faeces (via the bile). Elimination half-life: 0.5-3 hr.

Special Precautions

Gastric malignancy should be ruled out. Pregnancy, lactation, childn <1 yr. Monitoring Parameters Monitor Mg concentrations prior to initiation and periodically thereafter.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.